Newly added drugs in national reimbursement drug list (annual) vs Clinical trial country use share in China

Newly added drugs in national reimbursement drug list (annual) and Clinical trial country use share in China, compared over time.

Change the pair

Compare different indicators

The series

Over time

China, spaced by time . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.

Newly added drugs in national reimbursement drug list (annual)

Unit: count · 2 observations

Line chart
Newly added drugs in national reimbursement drug list (annual)Newly added drugs in national reimbursement drug list (annual). 2 observations from 2024 to 2025, ranging from 91 to 114. Latest value 114 (2025). 0 30 60 90 120 2019 2020 2021 2022 2023 2024 2025 91 114
Newly added drugs in national reimbursement drug list (annual)Newly added drugs in national reimbursement drug list (annual). 2 observations from 2024 to 2025, ranging from 91 to 114. Latest value 114 (2025). 0 30 60 90 120 2019 2020 2021 2022 2023 2024 2025 91 114
Newly added drugs in national reimbursement drug list (annual)Newly added drugs in national reimbursement drug list (annual). 2 observations from 2024 to 2025, ranging from 91 to 114. Latest value 114 (2025). 0 30 60 90 120 2019 2020 2021 2022 2023 2024 2025 91 114
View the underlying data
Newly added drugs in national reimbursement drug list (annual)
Period Type Value
2024 Actual 91
2025 Actual 114
Source: State Council, NHSA · CC BY 4.0 · Full series

Clinical trial country use share

Unit: % · 3 observations

Line chart
Clinical trial country use shareClinical trial country use share. 3 observations from 2019 to 2023, ranging from 10% to 15%. Latest value 15% (2023). % 0 3 6 9 12 15 2019 2020 2021 2022 2023 2024 2025 10% 15%
Clinical trial country use shareClinical trial country use share. 3 observations from 2019 to 2023, ranging from 10% to 15%. Latest value 15% (2023). % 0 5 10 15 2019 2020 2021 2022 2023 2024 2025 10% 15%
Clinical trial country use shareClinical trial country use share. 3 observations from 2019 to 2023, ranging from 10% to 15%. Latest value 15% (2023). % 0 5 10 15 2019 2020 2021 2022 2023 2024 2025 10% 15%
View the underlying data
Clinical trial country use share
Period Type Value
2019 Actual 10%
2021–2023 Actual 13%
2023 Actual 15%
Source: IQVIA · CC BY 4.0 · Full series

Provenance

Where these numbers come from

Newly added drugs in national reimbursement drug list (annual)

Total count of new drug varieties incorporated into a national reimbursement drug list during a catalog adjustment cycle.

2 observations in China · source organisations: State Council, NHSA

Clinical trial country use share

Percentage of total clinical trial country uses accounted for by a given region.

3 observations in China · source organisations: IQVIA

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related